Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.95K 82.72K 75.91K 143K 9.75M 145K 982K 384K 4.79M 380K 372K 16.58M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.95M 9.26M 8.49M 15.96M 1.09B 16.21M 110M 42.95M 537M 42.55M 41.63M 1.86B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Apricus Biosciences Inc Stock Nasdaq

Stocks

US03832V1098

Biotechnology & Medical Research

Valuation: Apricus Biosciences Inc

Latest news : Apricus Biosciences Inc

Analysts' recommendations: Apricus Biosciences Inc

Press Releases: Apricus Biosciences Inc

Managers and Directors: Apricus Biosciences Inc

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.93%	+6.97%	+62.83%	+67.97%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+43.68%	+84.56%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+3.28%	+422.58%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.03%	-16.54%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+30.99%	-3.58%	20.46B
GENMAB A/S	-1.34%	+0.51%	+25.02%	-30.27%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+32.54%	+544.11%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+165.62%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+23.62%	+178.38%	13.92B
Average	-1.04%	+1.28%	+40.62%	+170.95%	26.68B
Weighted average by Cap.	-0.87%	+2.10%	+41.18%	+135.69%

	2022	2023
Net sales	-	2.2 1.93 1.8 1.65 3.1 212.15 3.15 21.37 8.35 104.3 8.27 8.09 360.62
Net income	-73.53M -64.58M -60.06M -55.12M -104M -7.08B -105M -713M -279M -3.48B -276M -270M -12.04B	-37.88M -33.27M -30.94M -28.39M -53.35M -3.65B -54.17M -367M -144M -1.79B -142M -139M -6.2B
Net Debt	4.59M 4.03M 3.75M 3.44M 6.46M 442M 6.56M 44.51M 17.39M 217M 17.23M 16.86M 751M	11.23M 9.87M 9.17M 8.42M 15.82M 1.08B 16.06M 109M 42.56M 532M 42.16M 41.26M 1.84B

End-of-day quote Nasdaq Other stock markets
- ^USD	-